Positive Preliminary Results from PANCOSIL Phase 1 2 Study

OncoSil Medical Limited (ASX: OSL) has reported encouraging preliminary results from the PANCOSIL Phase 1–2 Investigator-Initiated Study, the first trial globally to evaluate CT-guided percutaneous administration of OncoSil™ for locally advanced pancreatic cancer (LAPC). Findings presented at the CIRSE 2025 Congress confirm that the approach is both safe and feasible. Out of 20 patients, no procedure-related deaths occurred, while 10% experienced Grade 3 serious adverse device effects, with both cases recovering.

The study achieved a 90% technical success rate, demonstrating reliable and reproducible delivery with patients under conscious sedation, reducing both procedure time and recovery needs. Importantly, median overall survival reached 20.6 months, significantly higher than the historical LAPC survival benchmark of approximately 13 months. Additionally, 15% of patients showed partial tumour responses by RECIST criteria. Based on these promising outcomes, OncoSil will pursue further regulatory approvals in FY26, aiming to broaden adoption among interventional radiologists and enhance multidisciplinary cancer care worldwide.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com